ReCor Medical adds 4 to expand its medical advisory board
ReCor Medical, which is backed by one of the largest life science investors in Europe in developing novel therapeutic ultrasound catheter technology, added 4 directors to its medical advisory board, which is now comprised of 9 members.
The board will conduct post-market clinical studies of ReCor’s next-generation Paradise percutaneous renal denervation system, the only renal denervation device based on ultrasound.
"We are very excited to add these outstanding physicians to our rapidly expanding medical advisory board," CEO Mano Iyer said in a prepared release. "Because early clinical results strongly suggest a significant competitive advantage for ReCor’s ultrasound-based Paradise system compared to radiofrequency-based standard of care for treating resistant hypertension patients, we look forward to our medical advisors’ special expertise in planning for ReCor’s post-market clinical studies."
The Paradise System treats resistant hypertension and allows for a more efficient renal denervation procedure, the company said. The device has CE Mark approval in the European Union, but it is not approved for sale or investigational use in the U.S.
TranS1 has new VP of regulatory, quality and compliance
Medical device company TranS1 (NSDQ:TSON) named Stephanie Fitts its new vice president of regulatory, quality & compliance.
Fitts was recently the director of regulatory affairs & compliance at Stryker‘s (NYSE:SYK) orthopedics division. Fitts’ resume also includes stints at Medtronic (NYSE:MDT), Cardiac Rhythm Management and Telectronics Pacing Systems.
Reddy is a managing director of Apollo Hospitals Enterprise Limited, a division of the Apollo Group, which is one of the largest hospital groups in Asia.
NCCN named new CEO
The National Comprehensive Cancer Network, a not-for-profit alliance of 21 of the world’s leading cancer centers, named Robert Carlson as CEO.
Carlson, who joined NCCN in 1983, comes from Stanford University Medical Center, where he served as professor of medicine in the division of oncology and Stanford Medical Informatics.
InVivo Therapeutics has senior director of manufacturing & engineering
Massachusetts-based InVivo Therapeutics (OTC:NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries and neurotrauma, appointed Bill D’Agostino as senior director of manufacturing & engineering.
Chowdhry worked at E.I. du Pont de Nemours as senior vice president and chief science & technology officer before retiring in 2010. Chen worked at Abbott (NYSE:ABT) as senior vice president of international nutrition before retiring in 2010.